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Monocarboxylate transporterPyroglutamate, also known as 5-oxoproline, is a structural analog of proline. This amino acid derivative is a
byproduct of glutathione metabolism, and is reabsorbed efﬁciently in kidney by Na+-coupled transport
mechanisms. Previous studies have focused on potential participation of amino acid transport systems in
renal reabsorption of this compound. Here we show that it is not the amino acid transport systems but
instead the Na+-coupled monocarboxylate transporter SLC5A8 that plays a predominant role in this
reabsorptive process. Expression of cloned human and mouse SLC5A8 in mammalian cells induces Na+-
dependent transport of pyroglutamate that is inhibitable by various SLC5A8 substrates. SLC5A8-mediated
transport of pyroglutamate is saturable with a Michaelis constant of 0.36±0.04 mM. Na+-activation of the
transport process exhibits sigmoidal kinetics with a Hill coefﬁcient of 1.8±0.4, indicating involvement of
more than one Na+ in the activation process. Expression of SLC5A8 in Xenopus laevis oocytes induces Na+-
dependent inward currents in the presence of pyroglutamate under voltage-clamp conditions. The
concentration of pyroglutamate necessary for induction of half-maximal current is 0.19±0.01 mM. The
Na+-activation kinetics is sigmoidal with a Hill coefﬁcient of 2.3±0.2. Ibuprofen, a blocker of SLC5A8,
suppressed pyroglutamate-induced currents in SLC5A8-expressing oocytes; the concentration of the blocker
necessary for causing half-maximal inhibition is 14±1 μM. The involvement of SLC5A8 can be demonstrated
in rabbit renal brush border membrane vesicles by showing that the Na+-dependent uptake of
pyroglutamate in these vesicles is inhibitable by known substrates of SLC5A8. The Na+ gradient-driven
pyroglutamate uptake was stimulated by an inside-negative K+ diffusion potential induced by valinomycin,
showing that the uptake process is electrogenic.+1 706 721 6608.
ll rights reserved.© 2010 Elsevier B.V. All rights reserved.1. Introduction
Pyroglutamate (also known as 5-oxoproline or pyrrolidone
carboxylate) is a cyclic lactam of glutamate. It is an intermediate in
γ-glutamyl cycle associated with glutathione metabolism where it is
generated by the action of γ-glutamyl cyclotransferase on γ-glutamyl
amino acids and γ-glutamyl peptides [1]. It is also produced by
enzymatic hydrolysis of N-terminal pyroglutamate present in a
variety of peptides and proteins [2]. Recent studies have shown that
pyroglutamate may have important biologic functions in the
regulation of amino acid transport [3,4]. Pyroglutamate is present in
free form in all animal tissues, plasma, and urine. The plasma levels
vary in the range of 10–40 μM under normal physiologic condi-
tions [5]. It is absorbed very effectively in the kidney. Normal urinary
excretion is ∼250 μmol/day in humans [6], which shows that the
fractional reabsorption of pyroglutamate in the kidney exceeds 85%.Excretion of pyroglutamate in urine increases several-fold in patients
with genetic defects in glutathione metabolism associated with the
deﬁciency of either glutathione synthetase or 5-oxoprolinase [7,8].
The increased excretion in these diseases can be explained by the
overproduction of 5-oxoproline, which exceeds the absorption
maximum in the kidney.
The effective reabsorption of pyroglutamate in the kidney
indicates the presence of efﬁcient transport systems for this
metabolite in the apical membrane of renal tubular cells. Several
early studies with puriﬁed renal brush border membrane vesicles
have provided evidence for a Na+-coupled electrogenic transport
process for pyroglutamate in the kidney, and for the involvement of
amino acid transport systems in the process [9–12]. Neutral amino
acids share the transport process with pyroglutamate. However, none
of the amino acids examined was able to block pyroglutamate uptake
in these membrane vesicles completely. In fact, at physiological
concentrations, none of the neutral amino acids tested was able to
inhibit pyroglutamate uptake by more than 10%. These ﬁndings
suggest that there are as yet unidentiﬁed transport systems
contributing to renal reabsorption of this compound.
1165S. Miyauchi et al. / Biochimica et Biophysica Acta 1798 (2010) 1164–1171The present studies were undertaken to evaluate the role of
SLC5A8 in the transport of pyroglutamate. SLC5A8 is a Na+-coupled
transporter for a variety of monocarboxylates such as lactate and
pyruvate [13], short-chain fatty acids [14–16], ketone bodies [17],
nicotinate and its structural analogs [18,19], and benzoate and its
derivatives [20]. It is expressed in the apical membrane of renal
tubular epithelial cells throughout the proximal tubule [21]. It plays
an obligatory role in the renal reabsorption of lactate [22,23]. What
prompted the present study was the ability of SLC5A8 to transport
nicotinate and the structural similarity between nicotinate and
pyroglutamate. Even though pyroglutamate is an amino acid
derivative, it exists predominantly as an anionic monocarboxylate at
physiological pH. This indicated that pyroglutamate may be recog-
nized by SLC5A8 as a transportable substrate. The present studies
show that it is indeed the case.2. Materials and methods
2.1. Materials
[14C]Nicotinate was purchased from American Radiolabeled
Chemicals (St. Louis, MO, USA). [3H]Pyroglutamate was purchased
from Moravek (Brea, CA, USA). Unlabeled monocarboxylates and
valinomycin were purchased from Sigma-Aldrich (St. Louis, MO, USA)
Human SLC5A8 andmouse Slc5a8 were originally cloned from human
intestine and mouse kidney, respectively [13,14].2.2. Transport of pyroglutamate via SLC5A8 in a mammalian cell
heterologous expression system
Human, mouse, and rat SLC5A8 cDNAs were expressed in the
human retinal pigment epithelial cell line HRPE using the vaccinia
virus expression technique [14]. The transport function of SLC5A8
was monitored by the uptake of [14C]nicotinate (15 µM) in the
presence of NaCl, and the interaction of pyroglutamate with the
transporter was investigated by studying the effect of pyrogluta-
mate on SLC5A8-mediated nicotinate uptake. HRPE cells trans-
fected with empty vector were used to measure background
transport activity. Uptake measurements in vector- and cDNA-
transfected cells were made in parallel under identical experimen-
tal conditions. The SLC5A8-speciﬁc transport was determined by
subtracting the transport values measured in vector-transfected
cells from the transport values measured in cDNA-transfected cells.
The uptake buffer was 25 mM Hepes/Tris (pH 7.5), containing
140 mM NaCl, 5.4 mM KCl, 1.8 mM CaCl2, 0.8 mM MgSO4, and
5 mM glucose. The inﬂuence of Na+ on the transport process was
assessed by monitoring the uptake of pyroglutamate in a Na+-free
buffer, which was prepared by substituting NaCl in the uptake
buffer with N-methyl-D-gluconate (NMDG) chloride isoosmotically.
The transport of pyroglutamate via SLC5A8 was also studied
directly by using [3H]pyroglutamate (0.25 μM). Saturation kinetics
of pyroglutamate uptake was studied by analyzing the data
according to the Michaelis–Menten equation to determine the
kinetic parameters Michaelis constant (Kt) and maximal velocity
(Vmax). Substrate selectivity was investigated by determining the
ability of various monocarboxylates to compete with pyrogluta-
mate for the uptake process. Na+-activation kinetics was investi-
gated by monitoring SLC5A8-speciﬁc pyroglutamate uptake in the
presence of increasing concentrations of Na+. The kinetic para-
meters, the Hill coefﬁcient (h, number of Na+ ions involved in the
activation process) and K0.5 (Na+ concentration necessary for half-
maximal activation of pyroglutamate uptake) were calculated by
ﬁtting the Hill equation to the experimental data. Results are given
as means±S. E. (n=4–6).2.3. SLC5A8-mediated transport of pyroglutamate using the Xenopus
laevis oocyte expression system
Capped cRNA from human SLC5A8 cDNA (cloned in pGH19, an X.
laevis oocyte expression vector) was synthesized using the mMES-
SAGE-mMACHINE kit (Ambion, Austin, TX, USA). Mature oocytes from
X. laevis were isolated by treatment with collagenase A (1.6 mg/ml),
manually defolliculated and maintained at 18 °C in modiﬁed Barth's
medium, supplemented with 25 µg/ml gentamicin as described
previously [14]. Oocytes were injected with 50 ng of cRNA. Water-
injected oocytes served as controls. The transport function of the
heterologously expressed SLC5A8 was monitored by two different
techniques, ﬁrst by measuring the uptake of [3H]pyroglutamate and
second by using an electrophysiological method. Uptake of [3H]
pyroglutamate (0.8 μM) in water-injected and cRNA-injected oocytes
was measured for 60 min in the presence or absence of Na+ (i.e., NaCl
buffer or NMDG chloride buffer) as described previously [14].
Electrophysiological studies were performed by the two-microelec-
trode voltage-clamp method. Oocytes were perifused with a NaCl-
containing buffer (100 mMNaCl, 2 mMKCl, 1 mMMgCl2, 1 mM CaCl2,
10 mM Hepes, pH 7.5), followed by the same buffer containing
pyroglutamate or other structurally compounds. Once the inward
currents plateaued off, the uptake was terminated by perifusing the
oocytes with a buffer in which NaCl was isoosmotically replaced with
NMDG chloride. The membrane potential was clamped at −50 mV.
The differences between the steady-state currents measured in the
presence and absence of substrates were considered as the substrate-
induced currents. In the analysis of the saturation kinetics of
substrate-induced currents, the kinetic parameter K0.5 (i.e., substrate
concentration necessary for induction of half-maximal current) was
calculated by ﬁtting the Michaelis–Menten equation to the values of
the substrate-induced currents. The Na+-activation kinetics of
substrate-induced currents was analyzed by measuring the sub-
strate-speciﬁc currents in the presence of increasing concentrations of
Na+. The data for the Na+-dependent currents were analyzed
according to the Hill equation to determine the Hill coefﬁcient (h,
the number of Na+ ions involved in the activation process) and K0.5
for Na+ (i.e., concentration of Na+ necessary for half-maximal
activation). Since expression levels varied signiﬁcantly from oocyte
to oocyte, kinetic analyses were done by normalizing the expression
levels. This was done by taking the maximally induced SLC5A8-
speciﬁc current in each kinetic experiment in individual oocytes as 1.
To investigate the current–voltage (I–V) relationship, step changes in
membrane potential were applied, each for a duration of 100 ms in
20-mV increments. Each experiment was repeated with four different
oocytes. The inﬂuence of ibuprofen, a blocker of SLC5A8 transport
function [19], was studied by analyzing the effect of this compound on
pyroglutamate-induced currents in SLC5A8-expressing oocytes. Each
experiment was repeated with at least 3 or 4 oocytes, and the data are
given as means±S. E.
2.4. Transport of pyroglutamate in rabbit kidney brush border membrane
vesicles
Brush border membrane vesicles were prepared from rabbit
kidney cortex by theMg2+-EGTA precipitation technique as described
previously [9–11]. The vesicles were preloaded with 25 mM Hepes/
Tris buffer (pH 7.5), containing 150 mM potassium gluconate. Uptake
of [3H]pyroglutamate (1 μM) in these vesicles was measured with a
15 s incubation in the presence of a NaCl-containing buffer (25 mM
Hepes/Tris, pH 7.5, with 150 mM NaCl). The dependence of
pyroglutamate uptake on Na+ was assessed by monitoring uptake
in a Na+-free buffer in which NaCl was substituted with KCl
isoosmotically. The ability of lactate, pyruvate, nicotinate, propionate
and butyrate (substrates for SLC5A8), and ibuprofen (blocker of
SLC5A8) to inhibit pyroglutamate uptake process was assessed in
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vesicles was monitored by measuring Na+-dependent uptake of [14C]
nicotinate (25 μM). This was done by measuring uptake in the
presence and absence of Na+ and then calculating the difference
between the two values. The interaction of pyroglutamate and other
structurally related compounds with Slc5a8 was assessed by the
ability of these compounds to inhibit Na+-dependent nicotinate
uptake. The experiments were performed twice with two different
preparations of membrane vesicles, and each experiment was done in
triplicate. Data are given as means±S. E.
2.5. Statistical analysis
Student's t test was used to determine the signiﬁcance of
differences between the means from two groups. Statistical signiﬁ-
cance among means of more than two groups was analyzed by one-
way analysis of variance (ANOVA). A pb0.05 was considered
statistically signiﬁcant.
3. Results
3.1. Structural relationship between nicotinate and pyroglutamate
Pyroglutamate, also known as 5-oxoproline, represents the
cyclized form of glutamate with the amino group and the carboxylate
group forming an intramolecular amide linkage. In proteins and
peptides, pyroglutamate is formed when N-terminal glutamine
cyclizes with concomitant deamidation. The presence of the intra-
molecular amide bond in pyroglutamate prevents protonation of the
imino group, and consequently pyroglutamate has only the carboxylic
acid group as the ionizable moiety (pKa=4.2). Therefore, it exists
predominantly as a monovalent anion at physiologic pH. In contrast,
proline, which does not have the intramolecular amide bond, exists
predominantly as a zwitterion at physiologic pH due to protonation of
the imino group (pKa=9.9) and deprotonation of the carboxylic acid
group (pKa=3.9). Pyroglutamate bears signiﬁcant structural resem-
blance to nicotinate, which also exists as a monovalent anion at
physiologic pH. The chemical structures of glutamate, glutamine,
proline, pyroglutamate, and nicotinate are given in Fig. 1.
3.2. Transport of pyroglutamate by SLC5A8 in a heterologous expression
system with a mammalian cell line
We ﬁrst used a mammalian cell expression system to investigate
the transport of pyroglutamate via SLC5A8. We expressed the cloned
human SLC5A8 in the human retinal pigment epithelial cell line HRPE
heterologously using the vaccinia virus expression technique. Cells
transfected with vector alone served as the control. The activity of
SLC5A8 was monitored by [14C]nicotinate uptake in the presence of
Na+. The uptake of nicotinate in SLC5A8 cDNA-transfected cells was
6-fold higher than in vector-transfected cells (data not shown).
SLC5A8-speciﬁc uptake was calculated by subtracting the uptake inFig. 1. Structures of glutamate, glutamine, pvector-transfected cells from the uptake in cDNA-transfected cells.
The uptake was linear up to 7.5 min. We studied the effects of
pyroglutamate, glutamate, glutamine, and proline on SLC5A8-speciﬁc
nicotinate uptake (Fig. 2). When present at 5 mM, pyroglutamate
caused 80–90% inhibition of SLC5A8-speciﬁc [14C]nicotinate uptake.
This inhibition was similar to the inhibition caused by 5 mM
unlabeled nicotinate. Glutamate and glutamine did not inhibit the
uptake. Proline stimulated the uptake to a small, but signiﬁcant extent
(pb0.01). These data show that pyroglutamate interacts with SLC5A8
and competes with nicotinate for the uptake process.
We then assessed the transport of pyroglutamate via SLC5A8
directly by monitoring the uptake of [3H]pyroglutamate in the same
heterologous expression system. Uptake of pyroglutamate in SLC5A8-
expressing cells was several-fold greater than in vector-transfected
cells (Fig. 3A). This uptake was Na+-dependent; there was no
detectable difference between uptake in SLC5A8-expressing cells
and vector-transfected cells when monitored in the absence of Na+.
Similar results were obtained with mouse Slc5a8. The transport of
pyroglutamate via SLC5A8 was inhibitable by the known substrates of
the transporter (Fig. 3B). This includes short-chain fatty acids
(acetate, propionate, and butyrate), nicotinate, pyruvate, and lactate.
Unlabeled pyroglutamate also competed with [3H]pyroglutamate for
the uptake process. Glutamine had no effect on SLC5A8-mediated
pyroglutamate uptake (pN0.05) whereas proline and glutamate
caused signiﬁcant inhibition (pb0.01). However, the inhibition
caused by proline and glutamate was much smaller than the
inhibition caused by SLC5A8 substrates.
The transport of pyroglutamate via SLC5A8 was saturable, with a
Michaelis constant of 0.36±0.04 mM (Fig. 4A). Na+-activation
kinetics indicated that the relationship between SLC5A8-mediated
pyroglutamate uptake and Na+ concentrationwas sigmoidal (Fig. 4B),
suggesting involvement of more than one Na+ in the activation
process. The data were ﬁt to the Hill equation and the Hill coefﬁcient,
which is the number of Na+ ions interacting with the carrier was
calculated. The value was 1.8±0.4, which indicates that for every
molecule of pyroglutamate transported, 2 Na+ ions are also
cotransported.3.3. Transport of pyroglutamate by SLC5A8 in a heterologous expression
system with X. laevis oocytes
We also investigated the transport of pyroglutamate via human
SLC5A8 using a different functional expression system. We expressed
the cloned human SLC5A8 in X. laevis oocytes by injection of cRNA.
Water-injected oocytes served as controls. First, we monitored the
uptake of [3H]pyroglutamate in water-injected and SLC5A8 cRNA-
injected oocytes. The uptake was ∼60-fold higher in cRNA-injected
oocytes than in water-injected oocytes (Fig. 5A). This uptake was
completely Na+-dependent; there was no signiﬁcant difference in
uptake between water-injected oocytes and SLC5A8-expressing
oocytes when measured in the absence of Na+ (6.7±0.7 pmol/roline, pyroglutamate, and nicotinate.
Fig. 2. Inhibition of SLC5A8-mediated nicotinate uptake by pyroglutamate. HRPE cells
were transfected with either pSPORT alone or human SLC5A8 cDNA. The expression of
the transfected cDNAwas facilitated by the vaccinia virus expression technique. Uptake
of [14C]nicotinate (15 μM) was monitored with a 15 min incubation, and SLC5A8-
speciﬁc transport of nicotinate was calculated by subtracting the uptake in vector-
transfected cells from the uptake in cDNA-transfected cells. Uptake measurements
were made in the absence or presence of pyroglutamate, proline, glutamate, glutamine,
and nicotinate (5 mM). Uptakemeasured in the absence of inhibitors was taken as 100%
(control), and uptake in the presence of inhibitors is given as percent of this control
value. The experiment was repeated two times and each experiment was done in
triplicate. Data represent means±S. E.
Fig. 3. Characteristics of SLC5A8-mediated pyroglutamate uptake. (A) Human SLC5A8
and mouse Slc5a8 were expressed functionally in HRPE cells using the vaccinia virus
expression technique. Cells transfected with vector alone served as controls. Uptake of
[3H]pyroglutamate (0.25 μM) was measured for varying time periods in the presence
(NaCl) or absence of Na+ (NMDG chloride). The experiment was carried out in
triplicate and repeated twice. The data represent means±S. E. (B) Inhibition of SLC5A8-
mediated pyroglutamate uptake by amino acids and monocarboxylates. HRPE cells
were transfected with human SLC5A8 cDNA or pSPORT. Vaccinia virus expression
technique was used to facilitate the expression of the transfected cDNA. Uptake of [3H]
pyroglutamate (0.25 μM) was measured with 15 min incubation in parallel in vector-
transfected cells and in cDNA-transfected cells, and SLC5A8-speciﬁc transport was
calculated by subtracting the uptake in vector-transfected cells from the uptake in
cDNA-transfected cells. Uptakemeasurements weremade in the absence or presence of
various amino acids andmonocarboxylates (5 mM). Uptakemeasured in the absence of
inhibitors was taken as 100% (control), and uptake in the presence of inhibitors is given
as percent of this control value. The experiment was done in triplicate and repeated
twice. Data are given as means±S. E.
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absence of Na+; pN0.05).
We have used previously an electrophysiological approach to
characterize the transport function of SLC5A8. Since the transporter
transports monocarboxylates with a negative charge along with more
than one Na+ per transport cycle, the transport process is electrogenic
resulting in depolarization of themembrane potential. Present studies
have shown that SLC5A8-mediated pyroglutamate transport is Na+-
dependent with involvement of more than one Na+. Pyroglutamate
exists mostly as a monovalent anion under physiologic conditions;
therefore, transport of this monovalent anion withmore than oneNa+
per transport cycle is expected to result in the transfer of one net
positive charge into oocytes, thus causing membrane depolarization.
Therefore, we used the two-microelectrode voltage-clamp technique to
investigate the electrogenic nature of SLC5A8-mediated pyroglutamate
transport. Superfusion of SLC5A8-expressing oocytes with pyrogluta-
mate (5 mM) induced marked inward currents under voltage-clamp
conditions (Fig. 5B). Such currents were not detectable in water-
injected oocytes (data not shown). The pyroglutamate-induced
currents in SLC5A8-expressing oocytes were absolutely dependent on
Na+ because the currents were not detectable under Na+-free
conditions. The anion chloride had no effect on pyroglutamate
transport via SLC5A8. The magnitude of the inward current induced
by pyroglutamate (5 mM) in the presence of Na+ but in the absence of
Cl− was 219±10 nA (3 different oocytes). Glutamate, glutamine, and
proline did not induce currents via SLC5A8, indicating that while
pyroglutamate is a transportable substrate for SLC5A8, glutamate,
glutamine, and proline are not. Current–voltage (I–V) relationship for
nicotinate- and pyroglutamate-induced currents indicates that the rate
of transport is dependent on membrane potential as expected of an
electrogenic process. The higher the membrane potential, the greater
were the currents induced by nicotinate and pyroglutamate in SLC5A8-
expressing oocytes (Fig. 5C). The maximal currents induced by
nicotinate (5 mM) and pyroglutamate (5 mM) at −50 mV are 323±
13 nA and 226±7 nA (4 different oocytes).
We then investigated the kinetic features of pyroglutamate
transport via SLC5A8 using the same electrophysiological approach.
Here we used pyroglutamate-induced currents as the measure of
transport rate. The transport process was saturable, with a Michaelisconstant of 0.19±0.01 mM (Fig. 6A). Na+-activation kinetics indi-
cated a sigmoidal relationship between pyroglutamate-induced
currents and Na+ concentration (Fig. 6B). Pyroglutamate-induced
currents reached a maximal steady state at 100 mM Na+. Determi-
nation of the Hill coefﬁcient using the Hill equation (Fig. 6B, inset)
gave a value of 2.3±0.2 for the Hill coefﬁcient, corroborating the data
obtained with the mammalian expression system that at least 2 Na+
are involved in the activation process. The Na+:pyroglutamate
stoichiometry of 2:1 provides the basis of the electrogenic nature of
the transport process.
Our previous studies have shown that ibuprofen is a blocker of
SLC5A8-mediated transport process [19]. Here we studied the effects
of this SLC5A8-speciﬁc blocker on SLC5A8-mediated pyroglutamate
transport. We monitored pyroglutamate transport electrophysiolog-
ically with superfusion of SLC5A8-expressing oocytes with pyroglu-
tamate (1 mM) in the presence of increasing concentrations of
ibuprofen (Fig. 7A). Pyroglutamate-induced inward currents in the
presence of Na+ under voltage-clamp conditions. Ibuprofen de-
creased themagnitude of these currents in a dose-dependent manner.
Kinetic analysis of this effect showed that the concentration of
Fig. 4. Saturation kinetics (A) and Na+-activation kinetics (B) of SLC5A8-mediated
pyroglutamate transport. (A) The vaccinia virus technique was used to express human
SLC5A8 in HRPE cells. Vector-transfected cells served as control. Uptake of pyroglu-
tamate was measured with a 7.5 min incubation in the presence of increasing
concentrations of pyroglutamate (50–2500 μM). The amount of [3H]pyroglutamate
was kept constant at 0.25 μM. SLC5A8-speciﬁc uptake was calculated by subtracting the
uptake in vector-transfected cells from the uptake in cDNA-transfected cells. Only the
SLC5A8-speciﬁc uptake was used for kinetic analysis. Inset: Eadie–Hofstee plot. (B)
SLC5A8-speciﬁc pyroglutamate uptake was measured in HRPE cells as described above.
Measurements were made in the presence of increasing concentrations of Na+ (2.5–
140 mM) with a ﬁxed concentration of Cl− (140 mM). Na+ concentrations were varied
by appropriately substituting NaCl with NMDG chloride. Data represent means±S. E.
for six determinations.
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3.4. Studies with rabbit renal brush border membrane vesicles
Slc5a8 is expressed exclusively in the brush border membrane of
proximal tubular cells in mouse kidney where it mediates active Na+-
coupled reabsorption of lactate and nicotinate [21]. Therefore, the
transport function of Slc5a8 can be studied using puriﬁed renal brush
border membrane vesicles. This provides an opportunity to investi-
gate the transport of pyroglutamate via Slc5a8 in a native state. We
ﬁrst studied the uptake of nicotinate in rabbit renal brush border
membrane vesicles as a measure of Slc5a8 activity. With 15 s
incubation, the uptake of nicotinate (15 μM) in these vesicles was 7-
fold greater in the presence of NaCl-containing medium than in the
presence of KCl-containing medium, indicating Na+-coupled trans-
port of nicotinate. We then monitored the effects of pyroglutamate
(5 mM) on nicotinate (15 μM) uptake in the presence and absence of
Na+. Pyroglutamate inhibited speciﬁcally the Na+-dependent uptake
(75%; pb0.05) (Fig. 8A). There was no signiﬁcant effect on Na+-
independent uptake (data not shown). At a concentration of 5 mM,
the amino acids proline, glutamate, and glutamine also caused
signiﬁcant inhibition of nicotinate uptake (30–40%; pb0.05). We
also studied the uptake of pyroglutamate directly in these vesicles.
The time course of uptake in the presence of Na+ showed the typicalovershoot phenomenon; the uptake was maximal at 30 s and then
reached equilibrium at 60 min (data not shown). The uptake at the
peak of the overshoot was ﬁve times greater than the equilibrium
value, indicating transient concentrative uptake. The uptake in the
absence of Na+ (i. e., KCl-containing medium) was slower than in the
presence of Na+ with no evidence of overshoot. The equilibrium
values were however similar both in the presence and absence of Na+.
These are typical characteristics of any Na+-coupled active uptake
process in puriﬁed renal brush border membrane vesicles. We then
assessed the effects of known transportable substrates for Slc5a8 and
ibuprofen, a blocker of SLC5A8, on pyroglutamate uptake (Fig. 8B).
The uptake of pyroglutamate (1 μM) was inhibited by ∼90% in the
presence of these compounds (5 mM). These data demonstrate that
pyroglutamate and these compounds compete for a common Na+-
coupled transport process in the renal brush border membrane. The
effect of a valinomycin-induced inside-negative membrane potential
on Na+-dependent pyroglutamate uptake was also investigated.
Uptake of pyroglutamate was stimulated by 12±3% (pb0.05) in the
presence of valinomycin (10 μM ﬁnal concentration), compared with
pyroglutamate uptake in the absence of valinomycin (data not
shown). These data show that Na+ gradient-driven pyroglutamate
uptake is electrogenic and that the uptake is associated with a net
transfer of positive charge across the membrane.
4. Discussion
Here we demonstrate for the ﬁrst time the involvement of the Na+-
coupledmonocarboxylate transporter SLC5A8 (also known as SMCT1) in
the renal reabsorption of the amino acid derivative pyroglutamate.
Because of the structural resemblance of pyroglutamate to proline,
previous studies focused on participation of amino acid transport
systems in the renal transport of this compound [9,10]. These studies
did show that neutral amino acids interactwith the transport system that
is responsible for pyroglutamate uptake in renal brush bordermembrane
vesicles. But, the maximum inhibition of pyroglutamate uptake caused
by any of the amino acids is ∼60%, indicating potential involvement of
other transport systems in the uptake process.
Lactate is a monocarboxylate with no structural resemblance to
pyroglutamate. This metabolite is reabsorbed in the kidney by an
effective Na+-coupled transport system [24–27]. Because of the lack
of signiﬁcant structural similarity between lactate and pyroglutamate,
interaction between these two compounds during the renal reab-
sorptive process was never suspected. The transporter responsible for
lactate reabsorption in the kidney has now been cloned [13]. This
transporter, known as SMCT1 (i.e., Sodium-coupled MonoCarboxylate
Transporter 1), mediates Na+-coupled transport of lactate with high
afﬁnity. It is expressed in the apical membrane of the proximal tubular
cells [21]. Absence of the transporter in the kidney leads to increased
urinary excretion of lactate [22,23], providing evidence for an
essential role of this transporter for absorption of lactate from
glomerular ﬁltrate. Studies with puriﬁed brush border membrane
vesicles have indicated that the renal transport system for lactate also
transports other monocarboxylates such as nicotinate and pyrazino-
ate [28]. These ﬁndings led us to test the ability of the cloned SLC5A8
to transport nicotinate [18,20].We found that SLC5A8, which is a Na+-
coupled transporter for linear-chain monocarboxylates such as
lactate, pyruvate, butyrate, propionate and acetate, also functions as
a Na+-coupled transporter for nicotinate, pyrazinoate, benzoate,
salicylate, and 5-aminosalicylate [18,20]. This was interesting because
it became evident for the ﬁrst time that SLC5A8 can accept as
substrates not only linear-chain monocarboxylates but also mono-
carboxylates with aromatic and heterocyclic ring structures. This new
insight into the structural features of SLC5A8 substrates led us to
revisit the transport mechanisms responsible for renal reabsorption of
pyroglutamate because of the structural similarity between pyroglu-
tamate and nicotinate.
Fig. 5.Demonstration of SLC5A8-mediated pyroglutamate transport in X. laevis oocyte expression system. (A) Uptake of [3H]pyroglutamate (0.8 μM)wasmeasured inwater-injected
oocytes and in SLC5A8 cRNA-injected oocytes in the presence or absence of Na+. Data represent means±S. E. for uptake in 10 different oocytes. (B) SLC5A8 cRNA-injected oocytes
were superfused with 5 mM pyroglutamate in the presence of NaCl (+Na+), NMDG chloride (−Na+), or sodium gluconate (−Cl−). Currents were monitored by the two-
microelectrode voltage-clamp technique. (C) Currents induced by pyroglutamate, nicotinate, proline, glutamate, and glutamine (5 mM) were monitored in SLC5A8 cRNA-injected
oocytes using the two-microelectrode voltage-clamp technique with varying membrane potential. Since the individual points for proline, glutamate and glutamine overlap and are
not distinguishable, only the data points for glutamine are shown.
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mate very effectively. We demonstrated this phenomenon with
human SLC5A8 as well as with mouse Slc5a8. Expression of cloned
human and mouse SLC5A8 in mammalian cells induced Na+-
dependent transport of pyroglutamate that was inhibitable by
various SLC5A8 substrates, including lactate and nicotinate.
SLC5A8-mediated transport of pyroglutamate was saturable with
a Michaelis constant of 0.36±0.04 mM. Na+-activation of the
transport process exhibited sigmoidal kinetics with a Hill coefﬁ-
cient of 1.8±0.4, indicating the involvement of more than one Na+
in the activation process. The ability of SLC5A8 to transport
pyroglutamate was also studied using a different expression
system. Expression of SLC5A8 in X. laevis oocytes induced Na+-
dependent inward currents in the presence of pyroglutamate under
voltage-clamp conditions. The concentration of pyroglutamate
necessary for induction of half-maximal current was 0.19±
0.01 mM. The Na+-activation kinetics was sigmoidal with a Hill
coefﬁcient of 2.3±0.2. Ibuprofen, a speciﬁc blocker of SLC5A8,
suppressed pyroglutamate-induced currents in SLC5A8-expressing
oocytes; the concentration of the blocker necessary for causing half-
maximal inhibition was 14±1 μM. We also studied the involve-
ment of the Na+-coupled lactate transport system in the kidney in
the transport of pyroglutamate directly using puriﬁed rat renal
brush border membrane vesicles. The Na+-dependent uptake of
pyroglutamate in these vesicles was inhibitable by lactate.
Itwas interesting to note that the amino acids proline, glutamate, and
glutamine caused 30–40% inhibition of nicotinate uptake in renal brushborder membrane vesicles. To the best of our knowledge, Na+-coupled
transport of nicotinate occurs only via SLC5A8. In X. laevis oocytes
expressing SLC5A8, there was no evidence of transport of these amino
acids via the transporter because none of these amino acids induced
signiﬁcant inward currents in these oocytes. Therefore, SLC5A8 does not
recognize amino acids as substrates. The ﬁndings that these amino acids
inhibited Na+-coupled nicotinate uptake in renal brush border
membrane vesicles suggest that the observed inhibitory effects may
be indirect due to amino acid-induced dissipation of transmembrane
electrochemical Na+ gradient. The renal brush border membrane
possesses several Na+-coupled electrogenic transport systems for
proline, glutamate, and glutamine. This includes SLC6A19 (B0AT1),
SLC6A20(SIT1), andSLC1A1(EAAT3). Thepresence of these aminoacids
at high concentrations (e.g., 5 mM) in the medium is expected to
reduce the transmembrane concentration gradient for Na+ as well as
generate an inside-positive membrane potential in renal brush
border membranevesicles due to transport via these Na+-coupled
electrogenic amino acid transporters. This will reduce the driving force
for the transport of pyroglutamate via SLC5A8. We speculate that the
observed 30–40% inhibition of SLC5A8 transport function by proline,
glutamate, and glutamine might be at least partly due to this indirect
effect. In contrast to these amino acids, other substrates of SLC5A8
inhibit 80–90% of Na+-coupled pyroglutamate transport in these
membrane vesicles. Based on these ﬁndings, we conclude that SLC5A8
is responsible for a predominant portion of renal reabsorption of
pyroglutamate and that the amino acid transport systemsplay relatively
only a minor role in the process.
Fig. 6. Saturation kinetics (A) and Na+-activation kinetics of SLC5A8-mediated
pyroglutamate transport in the X. laevis oocyte expression system. (A) Inward currents
were monitored in SLC5A8 cRNA-injected oocytes in the presence of increasing
concentrations of pyroglutamate in perfusion buffer. The experiment was done in 4
different oocytes. Since the expression levels of SLC5A8 varied to some extent in
different oocytes, the data were normalized by taking the maximal current induced by
the highest concentration of pyroglutamate (2.5 mM) as 1 in each oocyte and then
calculating the currents induced by pyroglutamate at other concentrations as a fraction
of this maximal current. Inset: Eadie–Hofstee plot. (B) Pyroglutamate (5 mM)-induced
inward currents were monitored in SLC5A8 cRNA-injected oocytes in the presence of
increasing concentrations of Na+ (2.5–100 mM). The concentration of Cl− was
maintained at 100 mM by appropriately substituting NaCl with NMDG chloride. The
experiment was done with 3 different oocytes, and the currents were normalized as
described above to adjust for variations in the expression levels in different oocytes.
Inset: Hill plot.
Fig. 7. Blockade of SLC5A8-mediated pyroglutamate transport by ibuprofen in X. laevis oocytes. (A) Pyroglutamate (1 mM)-induced currents were monitored in SLC5A8 cRNA-
injected oocytes in the presence of NaCl and increasing concentrations of ibuprofen. (B) The percent inhibition of pyroglutamate-induced currents by each concentration of
ibuprofen was calculated from the above experiment, and the data were used to determine the concentration of ibuprofen needed to cause 50% maximal inhibition by ﬁtting
Michaelis–Menten equation to the data. Inset: Eadie–Hofstee plot.
Fig. 8. Demonstration of the involvement of SLC5A8 in pyroglutamate uptake in
puriﬁed rabbit renal brush border membrane vesicles. (A) Uptake [14C]nicotinate
(25 μM) was measured in renal brush border membrane vesicles in the presence of
NaCl or KCl in the uptake medium using a 15 s incubation. Uptake measurements were
made in the absence or presence of pyroglutamate, glutamate, glutamine, or proline
(5 mM). Na+-dependent uptake, which was calculated by subtracting the uptake in the
presence of KCl from the uptake in the presence of NaCl, was taken as a measure of
SLC5A8 activity. The transport activity in the absence of inhibitors was taken as 100%
(control), and the transport activity in the presence of inhibitors was calculated as
percent of this control value. The experiment was repeated with three independent
vesicle preparations, and measurements were made in triplicate in each experiment.
Data are presented as means±S. E. (B) Uptake of [3H]-pyroglutamate (1 μM) was
measured in renal brush border membrane vesicles with a 15 s incubation in the
absence (control) or presence of various substrates or blockers of SLC5A8. When
present, the concentration of these compounds was 5 mM. The experiment was
repeated with three independent vesicle preparations, and measurements were made
in triplicate in each experiment. Data represent means±S. E.
1170 S. Miyauchi et al. / Biochimica et Biophysica Acta 1798 (2010) 1164–1171
1171S. Miyauchi et al. / Biochimica et Biophysica Acta 1798 (2010) 1164–1171References
[1] P. VanderWerf, A.Meister, Themetabolic formation andutilizationof5-oxo-L-proline
(L-pyroglutamate, L-pyrrolidone carboxylate), Adv. Enzymol. Relat. AreasMol. Biol. 43
(1975) 519–566.
[2] R.F. Doolittle, R.W. Armentrout, Pyrrolidonyl peptidase. An enzyme for selective
removal of pyrrolidonecarboxylic acid residues from polypeptides, Biochemistry 7
(1968) 516–521.
[3] R.A. Hawkins, R.L. O'Kane, I.A. Simpson, J.R. Vina, Structure of the blood–brain barrier
and its role in the transport of amino acids, J. Nutr. 136 (1 Suppl.) (2006) 218S–226S.
[4] R.A. Hawkins, I.A. Simpson, A. Mokashi, J.R. Vina, Pyroglutamate stimulates Na+-
dependent glutamate transport across the blood–brain barrier, FEBS Lett. 580 (2006)
4382–4386.
[5] R.W. Friesen, E.M. Novak, D. Hasman, S.M. Innis, Relationship of dimethylglycine,
choline, and betaine with oxoproline in plasma of pregnant women and their
newborn infants, J. Nutr. 137 (2007) 2641–2646.
[6] A.A. Jackson, C. Persaud, G. Werkmeister, I.S. McClelland, A. Badaloo, T. Forrester,
Comparison of urinary 5-L-oxoprline (L-pyroglutamtate) during normal pregnan-
cy in women in England and Jamaica, Br. J. Nutr. 77 (1997) 183–196.
[7] A. Larsson, M. E. Anderson, Glutathione synthetase deﬁciency and other disorders
of the gamma-glutamyl cycle, in: C. F. Scriver, A. L. Beaudet, W. S. Sly, D. Vallee
(Eds.), Metabolic Basis of Inherited Disease, 8th edition, McGrawHill, New York,
pp. 2205–2216.
[8] R. Njalsson, S. Norgren, Physiological and pathological aspects of GSHmetabolism,
Acta Paediatr. 94 (2005) 132–137.
[9] V. Ganapathy, R.A. Roesel, F.H. Leibach, Transport of 5-oxoproline into rabbit renal
brushbordermembranevesicles, Biochem. Biophys. Res. Commun. 105 (1982)28–35.
[10] V. Ganapathy, R.A. Roesel, J.C. Howard, F.H. Leibach, Interaction of proline, 5-
oxoproline, and pipecolic acid for renal transport in the rabbit, J. Biol. Chem. 258
(1983) 2266–2272.
[11] V. Ganapathy, F.H. Leibach, Electrogenic transport of 5-oxoproline in rabbit renal
brush-border membrane vesicles. Effect of intracellular potassium, Biochim.
Biophys. Acta 732 (1983) 32–40.
[12] H. Roigaard-Petersen, M.I. Sheikh, Renal transport of amino acids. Demonstration of
Na+-independent and Na+-dependent electrogenic uptake of L-proline, hydroxy-L-
proline and 5-oxo-L-proline by luminal membrane vesicles, Biochem. J. 220 (1984)
25–33.
[13] E. Gopal, J.J. Fei, M. Sugawara, S. Miyauchi, L. Zhuang, P.M. Martin, S.B. Smith, P.D.
Prasad, V. Ganapathy, Expression of slc5a8 in kidney and its role in Na+-coupled
transport of lactate, J. Biol. Chem. 279 (2004) 44522–44532.
[14] S. Miyauchi, E. Gopal, Y.J. Fei, V. Ganapathy, Functional identiﬁcation of SLC5A8, a
tumor suppressor downregulated in colon cancer, as a Na+-coupled transporter
for short-chain fatty acids, J. Biol. Chem. 279 (2004) 13293–13296.
[15] M.J. Coady, M.H. Chang, F.M. Charron, C. Plata, B. Wallendorff, J.F. Sah, S.D.
Markowitz, M.F. Romero, J.Y. Lapointe, The human tumour suppressor geneSLC5A8 expresses a Na+-monocarboxylate cotransporter, J. Physiol. 557 (2004)
719–731.
[16] V. Paroder, S.R. Spencer, M. Paroder, D. Arango, S. Schwartz Jr., J.M. Mariadason, L.
H. Augenlicht, S. Eskandari, N. Carrasco, Na+/monocarboxylate transport (SMCT)
protein expression correlates with survival in colon cancer: molec-
ular characterization of SMCT, Proc. Natl. Acad. Sci. U. S. A. 103 (2006) 7270–7275.
[17] . P.M. Martin, E. Gopal, S. Ananth, L. Zhuang, S. Itagaki, B.M. Prasad, S.B. Smith, P.
D. Prasad, V. Ganapathy, Identity of SMCT1 (SLC5A8) as a neuron-speciﬁc Na+-
coupled transporter for active uptake of L-lactate and ketone bodies in the
brain, J. Neurochem. 98 (2006) 279–288.
[18] E. Gopal, Y.J. Fei, S. Miyauchi, L. Zhuang, P.D. Prasad, V. Ganapathy, Sodium-
coupled and electrogenic transport of B-complex vitamin nicotinic acid by
slc5a8, a member of the Na+/glucose cotransporter gene family, Biochem. J.
388 (2005) 309–316.
[19] S. Itagaki, E. Gopal, L. Zhuang, Y.J. Fei, S. Miyauchi, P.D. Prasad, V. Ganapathy,
Interaction of ibuprofen and other structurally related NSAIDs with the
sodium-coupled monocarboxylate transporter SMCT1 (SLC5A8), Pharm. Res.
23 (2006) 1209–1216.
[20] E. Gopal, S. Miyauchi, P.M. Martin, S. Ananth, P. Roon, S.B. Smith, V. Ganapathy,
Transport of nicotinate and structurally related compounds by human SMCT1
(SLC5A8) and its relevance to drug transport in the mammalian intestinal tract,
Pharm. Res. 24 (2007) 575–584.
[21] E. Gopal, N.S. Umapathy, P.M. Martin, J.P. Gnanaprakasam, H. Becker, C.A. Wagner,
V. Ganapathy, P.D. Prasad, Cloning and functional characterization of human
SMCT2 (SLC5A12) and expression pattern of the transporter in kidney, Biochim.
Biophys. Acta 1768 (2007) 2690–2697.
[22] M. Thangaraju, S. Ananth, P.M. Martin, P. Roon, S.B. Smith, E. Sterneck, P.D.
Prasad, V. Ganapathy, c/ebpδ null mouse as a model for the double-knockout
of slc5a8 and slc5a12 in kidney, J. Biol. Chem. 281 (2006) 26769–26773.
[23] H. Frank, N. Groger, M. Diener, C. Becker, T. Braun, T. Boettger, Lactaturia and loss
of sodium-dependent lactate uptake in the colon of SLC5A8-deﬁcient mice, J. Biol.
Chem. 283 (2008) 24729–24737.
[24] M. Barac-Nieto, H. Murer, R. Kinne, Lactate-sodium cotransport in rat renal brush
border membranes, Am. J. Physiol. 239 (1980) F496–F506.
[25] K.E. Jorgensen, M.I. Sheikh, Renal transport of monocarboxylic acids. Heteroge-
neity of lactate-transport systems along the proximal tubule, Biochem. J. 223
(1984) 803–807.
[26] B. Barbarat, R.A. Podevin, Stoichiometry of the renal sodium-L-lactate cotran-
sporter, J. Biol. Chem. 263 (1988) 12190–12193.
[27] R. Mengual, M.H. Schlageter, P. Sudaka, Kinetic asymmetry of renal Na+-L-
lactate cotransport. Characteristic parameters and evidence for a ping pong
mechanism of the trans-stimulating exchange by pyruvate, J. Biol. Chem. 265
(1990) 292–299.
[28] S.E. Guggino, P.S. Aronson, Paradoxical effects of pyrazinoate and nicotinate on urate
transport in dog renal microvillus membranes, J. Clin. Invest. 76 (1985) 543–547.
